Coeptis Therapeutics Raises $4.3M for Cell Therapy: Funding to Drive Research, Manufacturing, and Regulatory Compliance

Coeptis Therapeutics closes $4.3M Financing Round

Coeptis Therapeutics (Linkedin), a leading biopharmaceutical company, has successfully raised $4.3 million to advance their cutting-edge cell therapy platforms for cancer, autoimmune, and infectious diseases. They are seeking partnerships with research institutions, manufacturers, and regulatory experts to accelerate their development and bring innovative treatments to patients.

Financing Amount: $4.3 million

Industry: Pharmaceutical Manufacturing

Employee Count: 201-500

CEO: Dave Mehalick (CEO Linkedin)

What Coeptis Therapeutics needs to buy: Coeptis Therapeutics is actively seeking partnerships with research institutions, manufacturers, and regulatory experts. Companies specializing in cell therapy production, supply chain management, and regulatory compliance can support Coeptis in advancing their therapies, ensuring quality manufacturing, and navigating complex regulatory landscapes.